<DOC>
	<DOC>NCT00998309</DOC>
	<brief_summary>To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Male or female subjects diagnosed with skin and soft tissue infection, sexuallytransmitted infection, and infection of the oral. Subjects must have no prior experience with Azithromycin SR. Patients not administered Azithromycin SR.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>skin infection</keyword>
	<keyword>soft tissue infection</keyword>
	<keyword>sexually-transmitted infection</keyword>
	<keyword>infection oral</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>